ArticleBritish journal of clinical pharmacology2017
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
Article in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.British journal of clinical pharmacology · 2021Pooled it
- Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Pooled it
- A cost-effectiveness analysis of baloxavir marboxil versus oseltamivir for seasonal influenza treatment in China.Frontiers in pharmacology · 2025Article
- Article
- Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States.Infectious diseases and therapy · 2024Article
- Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling.CPT: pharmacometrics & systems pharmacology · 2023Article
- Virtual twin for healthcare management.Frontiers in digital health · 2023Article
- Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.British journal of clinical pharmacology · 2022Article
- Economic evaluations of interventions against viral pandemics: a scoping review.Public health · 2022Article
- Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19.British journal of clinical pharmacology · 2021Article
- How COVID-19 has fundamentally changed clinical research in global health.The Lancet. Global health · 2021Review
- Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.Clinical pharmacology and therapeutics · 2021Review
- Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.CPT: pharmacometrics & systems pharmacology · 2021Article
- Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.Therapeutic innovation & regulatory science · 2021Review
- Early Treatment of COVID-19 Disease: A Missed Opportunity.Infectious diseases and therapy · 2020Article
- Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development.PharmacoEconomics · 2020Article
- Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.Clinical and translational science · 2020Article
- Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.Clinical and translational science · 2020Article
- Precision medicine technology hype or reality? The example of computer-guided dosing.F1000Research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsA modular interdisciplinary platform was developed to investigate the economic impact of oseltamivir treatment by dosage regimen under simulated influenza pandemic scenarios.
methodsThe pharmacology module consisted of a pharmacokinetic distribution of oseltamivir carboxylate daily area under the concentration-time curve at steady state (simulated for 75 mg and 150 mg twice daily regimens for 5 days) and a pharmacodynamic distribution of viral shedding duration obtained from phase II influenza inoculation data. The epidemiological module comprised a susceptible, exposed, infected, recovered (SEIR) model to which drug effect on the basic reproductive number (R
resultsOseltamivir 75 mg relative to no treatment reduced the median number of infected patients, increased change in quality-adjusted life years by deaths averted, and was cost-saving under all scenarios; 150 mg relative to 75 mg was not cost effective in low transmissibility scenarios but was cost saving in high transmissibility scenarios.
conclusionThis methodological study demonstrates proof of concept that the disciplines of pharmacology, disease epidemiology and health economics can be linked in a single quantitative framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.